Senators push pharma CEOs on drug prices
Inquiries from Congress continue to pile up with a growing focus on rising costs of insulin, as senators press pharmaceutical companies yet again to disclose drug pricing information.
Senate Health, Education, Labor and Pensions (HELP) Committee Ranking Member Sen. Patty Murray (D-Wash.) sent letters Tuesday to insulin manufacturers Sanofi (Euronext:SAN; NASDAQ:SNY), Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) requesting details about the rising cost of insulin over time and recent decisions to raise prices further. The Senate inquiries follow similar letters that House Democrats from the Energy and Commerce Committee sent to the companies Jan. 30 (see "House Democrats Ask Pharma CEOs to Explain Insulin Pricing")...